Article
RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.
Molecular cancer therapeutics - 1 Jul 2018
Bockorny Bruno, Rusan Maria, Chen Wankun, Liao Rachel G, Li Yvonne, Piccioni Federica, Wang Jun, Tan Li, Thorner Aaron R, Li Tianxia, Zhang Yanxi, Miao Changhong, Ovesen Therese, Shapiro Geoffrey I, Kwiatkowski David J, Gray Nathanael S, Meyerson Matthew, Hammerman Peter S, Bass Adam J
Abstract excerpt
The FGFR kinases are promising therapeutic targets in multiple cancer types, including lung and head and neck squamous cell carcinoma, cholangiocarcinoma, and bladder cancer. Although several FGFR kinase inhibitors have entered clinical trials, single-agent clinical efficacy has been modest and resistance invariably occurs. We therefore conducted a genome-wide functional screen to characterize mechanisms of...
Topics
Join the communities discussing this publication.